Pacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.26), $0.03 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $24.9 million versus the consensus estimate of $24.61 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.